Search results for "Cost-per-responder"

showing 1 items of 1 documents

A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study

2022

Abstract Background Psoriatic arthritis (PsA) is a chronic, immune-mediated, spondyloarthropathy characterised by musculoskeletal signs and symptoms with associated joint pain and tenderness. The average worldwide PsA prevalence is 133/100,000, while in the Italian population is 90–420/100,000. Traditionally, nonsteroidal anti-inflammatory drugs, glucocorticoid, and disease-modifying antirheumatic drugs have been used in the treatment of PsA. However, for those patients who are not adequately controlled with conventional therapies, the new biologics compounds represent a valid option. Biologic therapies have been shown to be more effective but also more expensive than conventional systemic …

Biological ProductsBiologicCostHealth PolicyArthritis PsoriaticPsoriatic arthritiTumor necrosis factor.Cost-per-responderBiological TherapyTreatment OutcomeReal-worldAntirheumatic AgentsHumansLongitudinal StudiesSecukinumabBMC Health Services Research
researchProduct